

Roadshow presentation

H1 2025/26

Making life easier_

Impact4: Setting the
standard of care at scale

Marque | User, Interventional Urology



Forward-looking statements

The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the information available to Coloplast at this time.

Heavy fluctuations in the exchange rates of important currencies, significant changes in the healthcare sector or major changes in the world economy may impact Coloplast's possibilities of achieving the long-term objectives set as well as for fulfilling expectations and may affect the company's financial outcomes.

Gavin Wood, President & CEO

Biography

Employment

Company Group Chairman, MedTech EMEA, Johnson & Johnson - 2022-2026

Responsible for leading a multibillion-dollar business with more than 7,000 employees.

Worldwide President, Wound Closure & Healing, Ethicon - 2019-2022

Responsible for the innovation agenda and the global P&L.

Executive Vice President, Global Commercial, Mölnlycke - 2018-2019

Responsible for leading the global commercial organisation.

In addition, Gavin Wood has held various commercial leadership positions across Johnson & Johnson from 2002 to 2015, as well as roles in strategy, business development, and marketing at Mölnlycke from 2015 to 2018.


Education

Bachelor of Arts degree in Law from Carleton University, Canada
MBA from Queen's University, Canada




Q2 2025/26 organic growth of 6% and 6% EBIT growth^{1,2}. FY 25/26 guidance: 5-6% organic growth and ~5% EBIT growth^{1,7}

Revenue growth



EBIT before special items



Q2 2025/26 highlights


- Organic growth was 6% and reported growth in DKK was 2%. Reported growth was negatively impacted by currencies (-4%-pts).
- Momentum uplift in Ostomy Care, as expected, with 7% growth driven by double-digit growth in the US, while Continence Care delivered 8% growth, driven by continued strong contribution from Luja™ for both male and female users.
- Voice & Respiratory Care grew 8% - good momentum in Laryngectomy; Tracheostomy impacted by order phasing, as expected.
- Wound & Tissue Repair declined 2% impacted by a challenging quarter in Kerecis, due to significant sales disruption from Medicare reimbursement change in the out-patient setting and negative impact from the voluntary product return in China.
- Interventional Urology grew 8%, driven by strong momentum in the US Men's Health business.
- EBIT² was DKK 1,820 million. EBIT² in constant currencies increased 6% compared to last year, while reported EBIT^{2,4} decreased 4%. The EBIT margin^{2,4} was 26%, against 27% last year, and includes around 120 basis points negative impact from currencies and around 50 basis points negative impact from Kerecis.
- Return on invested capital (ROIC) after tax before special items was 15%, on par with last year⁵. Strong free cash flow-to-sales ratio at 20%, compared to 15% last year⁶.
- As a result of the slower market recovery now anticipated in the skin substitutes outpatient setting, an impairment loss of DKK 3.0 billion has been recognised against the Kerecis goodwill, reducing the total carrying book value of Kerecis to around DKK 6 billion.
- The company will pay a half-year dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million.

FY 2025/26 guidance: organic growth now expected at 5-6%, EBIT growth^{1,7} now expected at ~5%, ROIC³ now expected at ~15%


- For organic growth we expect continued good momentum in Chronic Care and high-single-digit growth in Interventional Urology.
- Kerecis now expected to deliver ~0% growth, reflecting slower market recovery in the out-patient setting. In Advanced Wound Dressings, a slower momentum is expected in Europe, in addition to the negative impact from the product return in China in Q1-Q3.
- Reported growth in DKK is now expected at ~3%, with 2-3%-points negative impact from currencies.
- Capex-to-sales ratio still expected at ~5%. Effective tax rate still expected at ~22%.
- Special items is now expected around DKK 3.1 billion, reflecting the DKK 3 billion Kerecis impairment loss.

Q2 organic growth of 6%, driven by strong quarter in Chronic Care and Interventional Urology. Challenging quarter in Wound & Tissue Repair

Q2 2025/26 revenue by business area




Q2 2025/26 revenue by geography



Ostomy Care delivered the expected momentum uplift in Q2, with 7% organic growth and double-digit growth in the US

Ostomy Care performance




Q2 2025/26 highlights

- Q2 organic growth was 7% and reported growth was 3%.
- Following a soft start in Q1, momentum picked up in Q2 as expected, with the good momentum expected to continue into H2:
 - In Europe, the UK and Germany were the main growth contributors.
 - In the US, growth was double-digit, reflecting a continuation of the strong underlying momentum from Q1.
 - Emerging markets ex. China also delivered a solid contribution to growth, reflecting increased tender activity in the quarter.
 - China delivered negative growth due to the continued weak consumer sentiment and competitive pressures from domestic players in the community channel. A slight decline in sales is now expected for the full year.
- From a product perspective, the **SenSura[®] Mio** portfolio was the main contributor to growth, followed by the **Brava[®]** range of supporting products.
- The latest product launches within SenSura Mio, the black bags and the new 2-piece offering, both continues to perform well. Additional variants of the black bags were launched in H1, and further variants are expected throughout 2025/26.

Continence Care grew 8% in Q2 with Luja™ as the main contributor to growth, driven by both the male and female catheters

Continence Care performance




Q2 2025/26 highlights

- Q2 organic growth was 8% and reported growth was 4%:
 - Growth was driven by Europe, with solid contribution from the UK, France and Germany, as well as the US.
 - Growth in Emerging markets was led by LATAM.
- From a product perspective, **Luja™**, our intermittent catheter with a Micro-hole Zone Technology, was the main growth contributor in the quarter, driven by solid contribution from Europe, especially France and the UK, as well as the US. The male catheter continued to perform well, while the female catheter saw a strong uptake in the quarter driven by Europe.
- Growth in the **SpeediCath®** portfolio was driven by the standard and flexible catheters in the US and LATAM.
- Bowel Care continued its good momentum and made a strong contribution to growth in the quarter, driven by the **Peristeen®** portfolio in Europe, while Collecting Devices delivered flat growth.

Voice & Respiratory Care grew 8% in Q2, driven by continued good momentum in Laryngectomy

Voice & Respiratory Care performance




Q2 2025/26 highlights

- Q2 organic growth was 8% and reported growth was 5%:
 - **Laryngectomy** delivered high single-digit growth, which continued to be driven by an increase in the number of patients served in existing and new markets, and an increase in patient value driven by the **Provox® Life™** portfolio.
 - **Tracheostomy** posted mid single-digit growth, driven by continued solid underlying demand, partly offset by phasing in distributor markets. Growth in Tracheostomy is expected to be back-end loaded with pick up in momentum in the second half of the year.
- From a geographical perspective, growth was broad-based, driven by Europe and the US. Emerging markets continued to be the fastest growing region.

Wound & Tissue Repair declined 2% in Q2, impacted by a challenging quarter in Kerecis and the Advanced dressings product return in China

Wound & Tissue Repair performance



Q2 2025/26 highlights


- Q2 organic growth was -2% and reported growth was -6%.
- **Kerecis** delivered 0% organic growth:
 - Growth in the in-patient setting remained at a healthy double-digit level, albeit with a slight easing of momentum, compared with previous quarters.
 - Sales in the out-patient setting declined significantly due to the sales disruption from the Medicare reimbursement change, which has resulted in a broad pause in market activity. We expect these dynamics to persist into H2.
 - From a product perspective, **SurgiClose®** was the main growth contributor.
- **Advanced Wound Dressings** in isolation delivered -2% organic growth:
 - China detracted significantly from growth, impacted by the product return initiated in Q3 last year. Europe had a soft quarter across markets, particular France.
 - From a product perspective, **Biatain® Superabsorber** was the main growth contributor.
 - Coloplast has been awarded a five-year Innovative Technology contract by Vizient in the US for **Biatain® Silicone Fit**

1) Kerecis became part of organic growth on 1 September 2024.

2) Advanced Wound Dressings include the non-divested Skin Care business since December 2024.

Continued strong momentum in Interventional Urology in Q2 with 8% growth, driven by the US Men's Health business

Interventional Urology performance




Q2 2025/26 highlights

- Q2 organic growth was 8% and reported growth was 2%:
 - Men's Health in the US delivered a strong quarter and was the main growth contributor.
 - The **Titan® penile implant**, continued to perform well, with the patient funnel positively impacted by our patient support programme targeted at prospective patients.
 - In Kidney & Bladder Health, growth reflected solid contribution from the thulium fiber laser, Coloplast **TFL Drive**, as well as an easier baseline from the voluntary product recall last year.
- From a geographical perspective, the US was the main growth contributor, however, Europe also contributed nicely to growth in Q2.
- On February 18, 2026 Coloplast completed the acquisition of all shares and voting rights of **Uromedica**, a commercial stage medical technology company specialising in the treatment of stress urinary incontinence, with a solution highly complementary to our existing Men's Health business. The integration of Uromedica is progressing well and the acquisition has been well-received by our existing Men's Health customers.

Reported revenue in Q2 grew 2%, negatively impacted by currencies with around 4%-points

Q2 2025/26 Revenue development (mDKK)




Q2 2025/26 highlights

- Reported revenue increased by DKK 154 million or 2% vs. last year.
- Organic growth was 6% or DKK 405 million, driven by:
 - Momentum uplift in Ostomy Care, as expected, following a soft start in Q1, with double-digit growth in the US.
 - Solid performance in Continence Care, driven by Luja™ for both male and female users.
 - Continued good momentum in Voice & Respiratory Care, driven by Laryngectomy.
 - Challenging quarter in Wound & Tissue Repair, with 0% growth in Kerecis and negative impact from the voluntary product return in Advanced Dressings in China.
 - Continued strong momentum in Interventional Urology, driven by the US Men's Health business.
- Inorganic revenue contributed positively with 10 basis points to reported growth due to the acquisition of Uromedica.
- Foreign exchange rates had a negative impact of 3.8%-points on reported growth, mainly related to the depreciation of the USD, GBP and a basket of Emerging markets currencies against the DKK.

EBIT margin of 26%¹ in Q2: ~120 basis points negative impact from currencies and ~50 basis points negative impact from Kerecis

Q2 2025/26 EBIT margin development before special items (%)




Q2 2025/26 highlights

- **Gross margin** of 67%, compared to 68% last year.
 - Negative impact from currencies (~80 basis points) and ramp-up costs in Costa Rica and Portugal.
 - Positive impact from lower inflation on freight versus last year.
- **Operating expenses** amounted to DKK 2,897 million, a 2% increase from last year.
 - Distribution-to-sales ratio was 33%, against 34% last year, and reflects last year's extraordinary one-off logistics cost in the US, and lower sales costs in China this year.
 - The Admin-to-sales ratio was 4%, on par with last year.
 - The R&D-to-sales ratio was 4%, compared to 3% last year, driven by increased activity levels in Chronic Care and Kerecis.
- **EBIT before special items** amounted to DKK 1,820 million, a 4% decrease from last year. The reported EBIT margin before special items was 26%, against 27% last year, reflecting ~120 basis points negative impact from currencies and ~50bps negative impact from Kerecis.

Strong FCF-to-sales ratio at 20% in H1 2025/26 vs. 15% last year¹: positive development in working capital and lower net financial items

FCF development¹



—●— FCF-to-Sales (%)¹ — Cash Conversion² ■ FCF (DKKm)¹

H1 2025/26 highlights

- **Adjusted FCF** in H1 2025/26 was DKK 2,816 million, or a 33% increase, while **Adjusted FCF-to-sales** ratio was 20%, compared to 15% last year: (excluding acquisition costs this year and benefit from the divestment last year)
 - Favorable development in working capital. **NWC-to-sales** was 25%, against 26% at year-end 2024/25. NWC-to-sales ratio expected to be around 25% in FY 2025/26 and improve to around 24% in the Impact4 strategic period
 - Positive impact from lower financial items
 - Partly offset by higher CAPEX and higher income tax paid
- **CAPEX-to-sales** ratio was 6%, vs. 4% last year, and includes investments in the new manufacturing site in Portugal of around DKK 208 million.

1) FCF adjustments: FY 2025/26 adjusted for acquisition costs related to Uromedica. FY 2024/25 adjusted for the Skin Care divestment. FY 2023/24 adjusted for the extraordinary tax payment related to the transfer of Atos Medical's Intellectual Property (net impact of DKK 2.5 billion). FY 2022/23 adjusted for acquisitions, Mesh payments, and payment related to the formal resolution of the US Veteran Affairs matter; FY 2021/22 and FY 2020/21 adjusted for acquisitions and Mesh payments 2) Cash Conversion calculated as FCF ex. Mesh payments, interest payments, tax payments, M&A and marketable securities relative to EBIT before special items. Cash Conversion is trailing twelve months 3) FY 2024/25 adjusted for divestment of DKK 192 million 4) FY 2023/24 adjusted for the extraordinary tax payment of DKK 2.5 billion


FY 2025/26 guidance: organic revenue growth of 5-6% and EBIT¹ growth in constant currencies of around 5%

| | GUIDANCE 2025/26 | GUIDANCE (DKK) ² | KEY ASSUMPTIONS |
|--------------------------------|------------------|-----------------------------|--|
| SALES GROWTH | 5-6% | Around 3% | <ul style="list-style-type: none"> Chronic Care (incl. Voice & Respiratory Care): continued good momentum. Wound & Tissue Repair: Kerecis – organic growth expected to be around 0%, as market recovery in the out-patient setting following the Medicare reimbursement change is now expected at a slower pace than previously anticipated. Advanced Wound Dressings – negative impact from the product return in China in Q1-Q3 and softer momentum in Europe. Interventional Urology: growth expected to be high single-digit. Reported growth in DKK expected to be around 3% with around 2-3%-points negative impact from currencies. The skin care divestment and the Uromedica acquisition are combined expected to have a broadly neutral impact on the reported revenue growth. |
| EBIT GROWTH¹ | Around 5% | | <ul style="list-style-type: none"> Continued ramp-up in Costa Rica and Portugal. New Impact4 investments, including global technology investments, investments toward the new bowel care opportunity in the US, and investments related to Intibia. Kerecis EBIT margin of 0%. Immaterial impact from tariffs, as we expect our products to remain exempted. Special items are expected to be around DKK 3.1 billion and includes DKK 3 billion Kerecis impairment loss and around DKK 0.1 billion in acquisition related costs, including integration costs. Coloplast is closely monitoring developments in the Middle East and their impact on the business, including implications for demand, supply and cost inflation |
| ROIC³ | | Around 15% | <ul style="list-style-type: none"> Expected to be on par with last year's adjusted ROIC. |
| CAPEX-TO-SALES | | Around 5% | <ul style="list-style-type: none"> Investments to complete the new manufacturing site in Portugal, expected to be operational in Q4 25/26. Investments in new machines for existing and new products. IT and sustainability investments. |
| TAX RATE | | Around 22% | <ul style="list-style-type: none"> Coloplast's tax rate during the Impact4 strategic period is expected to be around 22%, benefiting from the recent IP transfers (Atos Medical and Kerecis). |



Introduction to Coloplast

Leading intimate healthcare



Our mission: *Making life easier for people with intimate healthcare needs*

A nearly 70-years old legacy, rooted in:


- *Delivering high quality products and services*
- *Continuously innovating with customers in mind*
- *A purpose-driven organisation*

Business model centred around customers, with innovative products and a strong service offering at the core

Chronic Care (~75% of revenues)



Acute Care (~25% of revenues)




Key services and Direct businesses




Coloplast has five business areas all with global sales presence

Group revenue 2024/25 *by segment*



Group revenue 2024/25 *by geography*



X = Coloplast's global market position

The market we compete in is characterised by stable fundamentals and structural growth

↑ Drivers

01. Demographics

Growing **elderly population** increases customer base for Coloplast products

02. Emerging markets

Expanding healthcare coverage for populations in emerging markets **increases addressable market**

↓ Limiters

01. Healthcare reforms

Economic restraints drive reimbursement reforms, **introduction of tenders**, and lower treatment cost

02. Surgical and medical trends


Earlier detection and cure, eventually reduces addressable market for Coloplast treatment products

Coloplast addressable market growth is 4-5%



Dorote | User, Continence Care

Stable underlying market drivers expected to continue in the next strategic period, with changes to pricing impact and China outlook



Coloplast has strong market positions in Chronic Care and great commercial potential in Acute Care

(X) Global market position

■ Europe
■ Other developed
■ Emerging

Addressable market

Size in DKK
Growth in %


Coloplast global market share

Coloplast regional market shares

Key competitors

Key drivers and limiters

Ostomy Care 1




35 - 40%

40 - 50%
15 - 25%
45 - 55%



- Ageing population
- Increasing access to healthcare
- Healthcare reforms
- Re-use of products outside Europe

Continenence Care 1




40 - 45%

45 - 55%
25 - 35%
40 - 50%



- Ageing population
- IC penetration potential
- Up-selling
- Healthcare reforms
- Commoditization

Voice & Respiratory Care (Laryngectomy) 1




~85%

80 - 90%
80 - 90%
95 - 100%



- Penetrate "white-space"
- Reimbursement in new geographies
- Compliance with usage recommendations
- New portfolio Provox® Life™

Interventional Urology 4




~15%

15 - 20%
15 - 20%
5 - 10%



- Ageing, obesity
- Under penetration
- Cost consciousness
- Clinical requirements
- Less invasive/office procedures

Wound & Tissue Repair 4/5




5 - 10% 4 Adv. dressings
5 - 10% 5 Biologics

5 - 10%
0 - 5%
5 - 10%



- Ageing, obesity, diabetes
- New technologies
- Healthcare reforms
- Competition
- Community treatment


A strong track record of delivering attractive financial performance and value creation rooted in mission and robust business model




A foundation built on innovation, featuring differentiated technologies backed by clinical evidence and strong relationships with healthcare professionals and customers – delivering industry-leading services and integrated solutions

We believe Coloplast can continue to deliver stable shareholder returns through ...

Organic growth and EBIT margin



FCF and ROIC



Value creation levers

- **Innovation and M&A executed in Strive25, combined with actions to address current performance**, provide a solid foundation for the new strategic period
- **New Business Unit structure and new ELT** to enable successful execution of the new strategy
- **Utilise strength of existing offering** of products and services in *Impact4*, while **setting an ambition for a step change in customer-centricity and innovation** during the period
- **Solidify market leading positions in Chronic Care** with continued rollout of Luja™, continued expansion of SenSura® Mio and accelerating reach of Provox® Life
- **Create an innovation leader with Wound & Tissue Repair** and aim for a larger share in the segment
- **Improve performance in Interventional Urology** by building on strength in Men's Health and transforming Women's Health with the Intibia™ launch
- **Step up in technology investments** to deliver enhanced user experience and efficiency across the group

1) FCF adjusted for Mesh payments and acquisitions/divestments. In addition, FY 2023/24 is adjusted for the extraordinary tax payment related to the transfer of Atos Medical's Intellectual Property paid in Q2 (net impact of DKK 2.5 billion in FY 2023/24), and FY 2022/23 is adjusted for the payment related to the formal resolution of the US Veteran Affairs matter.
 2) Before special items. Special items expenses of DKK 74 million in FY 2022/23, special items income of DKK 34 million in FY 2023/24, special items expenses of DKK 469 million in FY 2024/25, and special items expenses of DKK 3,060 million in H1 2025/26. 3) Adjusted for impact from the Kerecis IP transfer in YTD 2024/25



Introduction *to Impact4*


Setting the standard of care at scale



Value creation during *Impact4* will be measured through revenue and EBIT growth, as well as ROIC improvement



2030 Financial ambition:



1. In constant currencies. Before special items.
2. A linear improvement expected over the period.

Impact4 focuses on 4 strategic priorities that are essential for our success and value creation ambition

1



Set the standard of care and drive strong customer centricity, win customers over with innovative products and services backed by evidence.

2



Increase efficiency and reduce complexity to drive value by getting more out of what we have and investing in new capabilities and ways of working.

3



Technology including AI will be a key enabler for delivering a next-level user experience and for driving scale, through a significant investment in a foundation of new technology programs.

4



Build a winning company by fostering a culture of customer-centricity and high performance, while building a strong pipeline of leaders. Sustainability remains a strategic priority.



Grow through innovative customer offerings

Impact4

Step up innovation in products and services to become the most customer-centric company in our categories

Chronic Care:



Solidify our market leading position by providing:



- **Superior product offerings** with SenSura[®] Mio, Luja[™] and Provox[®] Life



- **Next level of services** for user and HCPs

Acute Care:



Create an innovation leader with the combination of AWD and Kerecis into **'Wound and Tissue Repair'**



Build on our strength in **Men's Health** and transform Women's Health with a successful launch of **Intibia[™]**





Unlock next level efficiency gains

Impact4

A paradigm shift in ways of working to enhance scalability and efficiency across the company



Drive **efficiency in Global Operations** to offset external headwinds and deliver gross margin accretion



Reduce complexity through portfolio simplification



Finalise integrations of Atos Medical and Kerecis and **drive synergies**



Drive **scalability** with Coloplast Business Support Centre in Poland and **establish new** Centre in Costa Rica to support growth and scale in the US





Embrace technology to elevate user experience and scale

Impact4

Step up technology investments to enable a best-in-class customer experience at scale



Utilise technology including AI to **enhance customer experience**



Utilise technology including AI to drive **efficiency improvements** across the business



Dedicated 5-year **technology programs** to support performance across the business





Cultivate a winning and sustainable company

Impact4

Enable strategy execution by shifting our company towards a faster and even more customer-centric organisation



Introduction of a new **Coloplast leadership program**, nurturing a high-performing and customer-centric culture in a large company



Develop **leadership for the future** by strengthening our executive succession pipeline




Sustainability remains an important strategic area with focus on **emissions, materials, reimbursement improvement and people**



All segments are expected to contribute to growth in the *Impact4* period, with Chronic Care as the largest contributor

Illustrative growth contribution during *Impact4*

Absolute revenue growth contribution until FY 2029/30 in bnDKK



Chronic Care:

- Growth above the market in **Ostomy and Continence Care** over the period, with solid contribution across regions ex. China
- **Voice and Respiratory Care** growth to continue in the 8-10% growth range
- **Innovation** a bigger contributor during *Impact4*

Acute Care:

- **Around double-digit growth for Wound and Tissue Repair** over the period, driven by Kerecis
- **Mid-single to high-single digit growth in Interventional Urology**, pick up in the latter part of *Impact4* driven by Men's Health and Intibia™ launch

We pursue dynamic resource-allocation to fuel high-potential areas by moving resources away from low-performance segments

Fuelling investments during *Impact4* through dynamic resource allocation:

From low-profitability and low-performance segments:

Skin Care divestment

China organisational restructuring

Interventional Urology cost optimisation

Focused innovation efforts on high-impact projects

Ongoing evaluation of further opportunities for resource reallocation



To high-potential and high-impact areas:

US Chronic Care

Kerecis

Intibia commercialisation

R&D and innovation

New business support centre for the US in Costa Rica

Technology programs including AI

Technology and AI investments to support company-wide efficiency enhancement:



Advance user experience




Enhance and scale one enterprise foundation



Enable Global Operations transformation

A leveraged P&L for the company with contribution across segments during *Impact4*, resulting in attractive growth in abs. EBIT

Illustrative development in absolute EBIT during *Impact4*
Absolute EBIT contribution until FY 2029/30 in bnDKK



1. In constant currencies. Before special items.

Gross margin:

- **Gross margin accretion** from Kerecis and Atos Medical and efficiency initiatives in Global Operations
- **Inflation** on raw materials expected to be stable
- **Negative impact** from continued wage increases in Hungary and diversified manufacturing footprint, however, ramp up cost decreasing over the period

EBIT development:

- **Leverage effect** in Chronic Care
- **Improvement in profitability** in Wound & Tissue Repair and Interventional Urology
- **Investments (incl. R&D, innovation and technology)** to drive growth, using dynamic recourse allocation

The new Global Operations plan will support our financial ambition and enable savings to offset cost headwinds in the strategy period

Key initiatives in GOP7



Throughput increase



New digital wave



Address direct spend

Highlights:

- More output from production machines
- Better utilisation of our assets

- Increased investments in technology and digital solutions
- Simplification and standardisation as a foundation

- Largest cost category in GO
- Opportunities from complexity reduction

Expected impact:


- Cost savings
- Capex reduction
- Increased output

- Cost savings
- Increase efficiency across the value chain
- Improve productivity

- Cost savings
- Offsetting headwinds from inflation


We will have sufficient capacity to meet demand and support growth until at least 2030; no factories expected after Portugal

Production volumes today and towards 2030*:




Strong focus on improving both FCF-to-sales and ROIC during the *Impact4* period

Adj. Free Cash Flow, mDKK



Ambition:
FCF-to-Sales
Above 20%

Adj. Return on Invested Capital, %




Ambition:
ROIC
Above 20%
in 29/30

Strong focus on improving FCF and ROIC in the *Impact4* period:

- **EBIT growth¹** in line with or above revenue growth over the period
- Improvement in **NWC to around 24%**
- Decrease in **capex-to-sales to around 4%** towards the end of *Impact4*
- **Tax rate** expected around 22% during the period
- **No significant M&A deals** expected, M&A strategy focused on bolt-on acquisitions

We will continue to provide attractive cash returns through stable dividend payout

Coloplast cash distribution to investors



Capital allocation considerations

- **Dividend payout:** continue to return excess cash to shareholders through dividends and share buy-backs, with a long-term pay-out ratio at 60-80% of net profit.
- Dividend is paid twice a year - after the half-year and full-year financial reporting.
- Total dividend of DKK 23.00 per share for 2024/25 compared to DKK 22.00 per share for 2023/24.
- Coloplast will pay a half year interim dividend of DKK 5.00 per share.
- **Share buy-back programme** serves to hedge employee share options. Expected to resume during Impact4.
 - Coloplast will not initiate a share buy-back program in FY 2025/26 as treasury shares are sufficient to hedge outstanding employee share options.
- **Leverage ratio:** commitment to bring the NIBD/ ratio down to around 1.5x towards 2029/30.

1) Dividends paid out in the year are the actual cash payments of which the majority relates to dividend proposed in the previous financial year.

2) Pay-out ratio is before special items and calculated as dividend proposed in the financial year/net profit for the financial year. After special items, the pay-out ratio for 24/25 was 143%

We will continue to focus on key sustainability and social metrics

Reduce our environmental impact:



Emissions reduction

- Scope 1+2 • 90% emission reduction by 2029/30
- Scope 3 • 10% emission reduction per product by 2029/30*
- Net zero by 2045

Use less materials

- Materials • 15-20% reduction in products and packaging by 2029/30

*Adjusted from previously 50% reduction per product by 2030

Benefit society and our employees:



Positively impact people

- Users and Healthcare professionals
 - Reimbursement improvements in around 5 markets
- Employees
 - Safety: LTIs of 1.5 PPM or below
 - Employee Engagement score in the top quartile of our industry
 - Diversity in leadership of 40%
 - Code of conduct: 100% completion

Our environment continues to be complex; internal and external risks are monitored closely

Internal factors



Stable quality, supply and distribution of products



Contribution from launches



Execution excellence



Direct businesses increase operational complexity

External factors



Geopolitical impact on supply chains, tariffs and data handling



Reimbursement reforms and price pressure



Changes in competitive environment



Increased regulation & compliance requirements



The Coloplast Executive Leadership Team



Gavin Wood
President and CEO
Joined Coloplast May 1, 2026



Anders Lonning-Skovgaard
EVP, CFO
With Coloplast since 2006



EVP, People & Culture



Allan Rasmussen
EVP, Operations
With Coloplast since 1992

Chronic Care



Caroline Vagner Rosenstand
EVP, Chronic Care Commercial
With Coloplast since 2015



Rasmus Just
EVP, Chronic Care R&D
With Coloplast since 2025

Acute Care



Fertram Sigurjonsson
EVP, Wound & Tissue Repair
With Coloplast since 2023



Kevin Hardage
EVP, Interventional Urology
Joined Coloplast Feb. 9, 2026

With *Impact4*, we put customers at the centre, aiming to help 4 million people long-term



Chronic Care

Leading intimate healthcare

Pete | User, Continence Care



Chronic Care: Five strong business areas with market leading positions

Ostomy Care



~36%

#1

Continence Care



~29%

#1

Bowel Care



~3%

#1

Laryngectomy Care



~6%

#1

Tracheostomy Care



~2%

#4



Share of group revenue*



Market position

Includes Intermittent Catheters and Collecting Devices

Introducing Chronic Care – our new Business Unit that plays to our strengths across the chronic space

Characteristics of the chronic business areas



Stable flow of loyal users with similar pathways and lifecycle



Market leaders in a stable competitive environment



Solid reimbursement levels, with risk of reforms



Services and support are increasingly important



Strong commercial model in place



Similar macro-trends impacting the business




Succeeding in our chronic categories requires a maturity-based approach tailored to each business area and region

Impact4

Based on BA and regional maturity we will expand through...


1 Establishing reimbursement



Example:

- Bowel Care in the US


2 Penetrating and expanding the market



Example:

- Intermittent Catheters use for Multiple Sclerosis patients


3 Driving adherence to treatment



Example:

- Laryngectomy in the US
- Tracheostomy in UK

4 Expand and upgrade through innovation



Example:

- Ostomy Care in Europe

Business areas strategic priorities and ambitions within *Impact4*

Strategic priorities

Chronic Care

- **Ostomy Care:** Solidify market leading position with SenSura Mio
- **Intermittent Catheters:** Make Luja the new standard of care
- **Bowel Care:** Develop the market and double our reach
- **Laryngectomy Care:** Utilise strong foundation to accelerate reach
- **Tracheostomy Care:** Set the standard and transform care

Enablers

- **Services:** Provide the best customer experience and be the partner of choice
- **Innovate with impact:** Envision life after surgery, inspired by how it was before

2030 impact

Organic revenue growth above the market across business areas over the period

Our ambition:

Solidifying our market leading position by providing the best customer experience and being the partner of choice for our users, HCPs and payors

Meeting needs, changing lives by:



Offering **superior products** with innovation leadership backed by clinical evidence



Providing **industry-leading services** and **integrated solutions** giving our customers the best experience and help ease their burden



Leveraging our **strong commercial model** – winning and retaining users and driving treatment adherence



To unlock growth, we want to utilise our strong service platform to elevate the customer experience across all touchpoints

Strong platform in place and strategic rationale



+30 countries
with patient support programs



+15 countries
with direct delivery



 **Coloplast Professional** |  **Atos Learning Institute**
To support clinicians



Multiple clinical studies
to justify reimbursement

Direct presence (non-exhaustive)


 **Coloplast Charter**
~30% MS

 **Atos Care**
~85% MS

 **Coloplast Homecare**
~15% MS

 **Lilial**
~25% MS

 **Comfort Medical**
5-10% MS

 **Coloplast**
Online channel
~65% MS

- High level of service
- Ensure successful experience for users
- Target the full value pool
- Direct access to consumers
- Direct relationship with payers
- Protect patient pathway
- Improve patient outcomes
- Introduce innovative products
- Control and continuity of product supply

We will continue to develop and deepen relationships through customer centricity to be the partner of choice



Patient: We support patients beyond products; through education, community, issue resolution, prescription management and access to newest technologies to help them live the life they want.



Healthcare professionals: We support and ease clinical burden by offering tailored education, pragmatic tools, and seamless discharge processes, so clinicians can focus on care.



Payers: We aim to prove the value of our services through clinical evidence and outcomes; transforming how care is delivered and reimbursed.

Luja™, our new catheter platform with Micro-hole Zone Technology™ addresses key UTI risk factors

Continence Care – preventing UTIs remains one of the biggest unmet needs



45 % of users describe UTIs as their greatest challenge in life¹
(2.7 UTIs per user on average every year)¹



47 % of users are worried whether they have emptied their bladder²

Luja™ – a new intermittent catheter with a Micro-hole Zone Technology, addressing key UTI risk factors

- Launch of Luja for men and women concluded, both products available in 13 countries
- Launch supported by compelling clinical evidence³



UTI risk factors⁴ addressed by Luja™



UTI risk factor:
Non-hygienic technique



UTI risk factor:
Urethral trauma




UTI risk factor:
Residual urine



UTI risk factor:
Bladder micro trauma

In US Ostomy Care, product launches and stronger focus on execution position us well for continued share gains

US pathway



Continue to increase market share across channels through:



Innovation

Expand penetration with new **SenSura® Mio 2-piece click coupling** in existing accounts and convert new opportunities



Win customers in the community with **SenSura Mio in black**




Commercial execution

Strengthen commercial execution to win access in acute and post-acute accounts


Medline partnership

Continued share gains in the acute channel

Bags and plates acute share



Total ostomy care market share



Based on Coloplast estimates

Coloplast has been awarded access to key GPOs, ensuring a level playing field in ~75% of acute accounts in US Ostomy Care

Coloplast has been awarded access to [Vizient](#) and [Premier](#), the two largest GPOs in the US

| | Acute members ¹ | Estimated Acute share ² | Contract expiry date | Contract length | Contract Type |
|--|----------------------------|------------------------------------|----------------------------|-------------------------------------|---|
|  PREMIER | 3,600 | ~25% | 31 March 2029 ³ | 3 years (incl. 3-year extension) | Multisource Coloplast, Hollister, Convatec |
|  vizient ^{TM*} | 7,500 | ~50% | 30 June 2028 ³ | 3 years (incl. 2-year extension) | Multisource Coloplast, Hollister, Convatec |
|  HEALTHTRUST ^{TM*} | 1,400 | ~15% | 30 September 2026 | 3 years | Single source Hollister |

Source: Coloplast, GHX


- 1) Acute members can be part of more than one GPO
- 2) Coloplast estimates based on primary GPO affiliation
- 3) Expiry dates reflects recent contract extensions

* Third party trademarks are the property of their respective owner(s)

In US Continence Care, we drive the upgrade of the market to hydrophilic catheters and aim to set a new standard of care with Luja

We are driving the upgrade to hydrophilic-coated catheters in the US

Hydrophilic catheters as % of Coloplast US intermittent catheters sales



IC code reform to shift market further towards hydrophilic catheters



From 2026, IC codes are split into HCIC and non-HCIC at the same Medicare reimbursement rate



Large educational undertaking to inform and train all prescribing HCPs and DMEs



DMEs will renegotiate funding rates for HCIC with commercial payers

US IC reimbursement categories now includes new dedicated codes for hydrophilic catheters, implemented 1 January 2026

On 16 August 2024, CMS issued a final coding decision*, revising the existing codes and introducing three new codes dedicated to hydrophilic intermittent catheters as of 1 January 2026.

Illustrative

| Straight catheter | Bended tip (male only) | Sets (users w. +2 UTIs/year) |
|---|--|---|
| A4351- Uncoated | A4352- Uncoated | A4353- Uncoated |
| A4295- Hydrophilic | A4296- Hydrophilic | A4297- Hydrophilic |
| Highest volume | Highest CAGR | Highest value/user |
| Coloplast latest offering: SpeediCath Soft | Coloplast latest offering: Luja Coude | Coloplast latest offering: SpeediCath Flex Set |

New codes





Acute Care


Leading intimate healthcare



The Acute Care business unit consists of two key business areas




Share of group revenue*


Market Position

Product areas

Introducing Acute Care

Characteristics of the acute business areas



Mostly about winning
in hospitals and
surgery centers



Physicians and
surgeons are the key
customer



Innovative product
pipeline expands share
& adoption



Limited recurring
revenue, new patient
flow essential



Innovation, evidence
and reimbursement
commands premium



Exploring adjacencies
to compete long term



Tony
User, Interventional
Urology

Business areas strategic priorities and ambitions within *Impact4*

Strategic priorities

Interventional Urology

- Develop the market, innovate and expand in Men's Health
- Transform Women's Health with OAB entry
- Improve profitability in Kidney and Bladder Health

2030 impact

Mid single- to High single-digit organic revenue growth over the period

Wound & Tissue Repair

- Build our US market share for the combined business
- Continue innovating in existing indications and explore new indications
- Expand globally leveraging combined infrastructure
- Invest in combination products, digital growth and AI

Around double-digit organic revenue growth over the period

Interventional Urology is organised into three business areas, helping patients with urological conditions

Interventional Urology at a glance

mDKK, FY 24/25




Revenue by business area

mDKK, FY 24/25



Revenue by region

mDKK, FY 24/25



Men's Health

Treatment of:

Erectile dysfunction



Solutions:

Portfolio of products for male reconstructive surgery, including flagship Titan penile prosthesis

Women's Health

Treatment of:

Stress urinary incontinence

Pelvic organ prolapse



Solutions:

Portfolio of slings, meshes, and surgical tools to facilitate implant procedures

Kidney & Bladder Health

Treatment of:

Kidney stone disease

Bladder drainage

Voiding dysfunctions

Prostate disorders




Solutions:

Flagship brands that provide capital equipment and a comprehensive portfolio of single-use devices

The market remains highly attractive and poised for long-term growth

Addressable market¹:



Market dynamics:

- High number of patients with unmet needs
- Continued favorable reimbursement trends in the US
- Significant space for innovation
- Attractive assets in adjacent segments
- Focus areas (MH and WH incl. OAB) growing faster than average market growth

Strategic opportunities:



Male Stress Urinary Incontinence



Prostate Cancer



Benign Prostatic Hyperplasia

With Intibia™*, Coloplast obtained an option to enter the attractive OAB market worth around 1bn USD.

Overactive bladder (OAB) market

+80m people globally suffer from OAB symptoms

~40% of the OAB patient population seek treatment

~3m are candidates for 3rd line therapies¹⁾

1bn USD 3rd line therapies market, growing high-single digits

Acquisition Nine Continents Medical Inc in 2020



With the acquisition of Nine Continents Medical Inc, Coloplast obtained an early-stage implantable tibial nerve stimulation treatment for urgency urinary incontinence (UUI).

The device is an implantable tibial nerve stimulator (ITNS), a miniaturized, self-powered unit placed in the lower leg under local anesthesia during a short, minimally invasive procedure.

Coloplast began pivotal studies in early 2022, with the ambition to obtain pre-market approval for a Class III device in the US and EU market. Anticipated launch of Intibia, pending FDA approval.

Transaction

The acquisition price consisted of a USD 145 million upfront cash payment and an additional contingent future milestone payment. The transaction was debt financed.

*Investigational device currently under development. Not cleared or approved for sale in U.S. or any market

¹⁾ Existing 3rd line therapies for OAB include sacral neuromodulation, botox and percutaneous tibial nerve stimulation (PTNS)

Why Implantable Tibial Nerve Stimulation (ITNS)?

Less invasive procedure than SNS

ITNS complete in single procedure
Procedure under local anesthesia

Less time-intensive


Intibia may reduce the need for frequent office visits

Established data on tibial nerve stimulation efficacy

PTNS established clinical efficacy
Urologist familiar with PTNS story


Why Coloplast's ITNS solution?

- ✓ Reduce the need for patient compliance in therapy
- ✓ Long battery life
- ✓ Focused stimulation at the nerve




Kerecis strong US footprint in combination with AWD global infrastructure forms Wound & Tissue Repair growth foundation


Kerecis revenue split by region



Advanced Wound Dressings revenue split by region^{1,2}



Combined Wound & Tissue Repair revenue split by region⁴




- North America and European markets are largest revenue hubs post-combination
- Large portion of Kerecis growth projected to occur in the US³, pointing towards North America accounting for ~60% of combined revenues towards the end of the *Impact4* period

Based on FY 24/25


■ Europe ■ Other Developed Markets ■ Emerging Markets

Wound & Tissue Repair revenue split by product segments⁴, FY 24/25




Kerecis revenue split, FY 24/25

By wound type:



By care setting:




A strong product portfolio and even stronger pipeline will enable WTR to become a bigger player in the attractive Wound Care market

An attractive and growing market¹...
Market size in bnDKK

Advanced Dressings
growing 2-4%

Coloplast
Market share 5-10%




Biologics
growing 6-8%

External Devices (NPWT)
growing low-single digit

kerecis
Market share 5-10%

...being addressed with innovative technologies...



Product Expansions across categories

...and a strong pipeline

Product development and strategic opportunities

Enter new indications and adjacent segments (e.g. Tendon Protection, Devices)


Combination products (e.g. SurgiClose Silicone)

Launch next generation Kerecis fish-skin technology

AI & App Development

Fish skin – biological advantage resulting in a clinically differentiated and unique technology for healing of severe wounds

Kerecis fish skin – gently processed, preserving natural structure...




Advantages of the fish-skin technology:

- **High resemblance to human skin:** three-dimensional structure, thickness, mechanical properties, porosity and cell size
- **Biological advantage:** No viral transmission risk from cold water fish to humans allows for gentle processing
- **Gentle processing:** maintains the fish skin’s 3D structure, mechanical properties, chemical complexity, and molecular content (proteins, elastins, glycans, and lipids)
- **Scalable, low-risk production:** sourcing, scale removal, drying, packaging, sterilization and logistics
- **Clinical use:** debride, apply, cover, offload, repeat if needed

...and backed by compelling clinical evidence:

Key findings from recent studies:

- Kerecis healed 66% more deep DFUs relative to SOC by week 16, $P < 0.001$ (Odinn study, 2024. N=255)
- By 12 weeks, 56.9% of superficial DFUs in the IFSG group had healed, while only 31.4% of superficial DFUs in the control group had healed, $P = .0163$ (LEG study, published 2023. N=102)



*Copyright Steve Gschmeissner/Science Photo Library



Financials

Leading intimate healthcare

Christopher | User, Ostomy Care



H1 organic growth of 6% driven by Chronic Care and Interventional Urology. Wound & Tissue Repair limited contribution in challenging H1

H1 2025/26 revenue by business area


| Business area | Reported revenue mDKK | Organic growth | Share of organic growth |
|--------------------------|-----------------------|----------------|-------------------------|
| Ostomy Care | 5,010 | 5% | 32% |
| Continence Care | 4,588 | 7% | 40% |
| Voice & Respiratory Care | 1,181 | 8% | 11% |
| Wound & Tissue Repair | 1,895 | 1% | 3% |
| Interventional Urology | 1,453 | 8% | 14% |
| Coloplast Group | 14,127 | 6% | 100% |

H1 2025/26 revenue by geography

| Geographic area | Reported revenue mDKK | Organic growth | Share of organic growth |
|-------------------------|-----------------------|----------------|-------------------------|
| European markets | 7,973 | 6% | 55% |
| Other developed markets | 3,834 | 7% | 33% |
| Emerging markets | 2,320 | 4% | 12% |
| Coloplast Group | 14,127 | 6% | 100% |

Reported revenue in H1 grew 1%, with 4%-points negative impact from currencies and 0.5%-point detracting from Skin Care divestment

H1 2025/26 Revenue development (mDKK)




H1 2025/26 highlights


- Reported revenue increased by DKK 171 million or 1% vs. last year.
- Organic growth was 6% or DKK 789 million, driven by:
 - Broad-based growth in **Ostomy Care** across regions, except China.
 - Solid performance in **Continence Care**, with Luja™ the main contributor to growth.
 - **Voice & Respiratory Care** growth driven by continued good momentum in Laryngectomy. Tracheostomy negatively impacted by phasing.
 - **Wound & Tissue Repair**:
 - Kerecis at 5% growth, with good, healthy growth in in-patient setting, declining sales in out-patient setting due to the Jan 1 reform.
 - Declining sales in dressings due to product return in China of DKK ~50 million.
 - Strong H1 in **Interventional Urology** driven by the US Men's Health business.
- Inorganic revenue had a negative impact of 50 basis points on reported growth, due to the divestment of Skin Care in December 2024.
- Foreign exchange rates had a negative impact of 4%-points on reported growth, mainly related to depreciation of the USD, GBP and a basket of Emerging markets currencies against the DKK.

Coloplast revenue development by business area


Ostomy Care




Interventional Urology




Voice & Respiratory Care¹




Continence Care



Wound & Tissue Repair²




Group revenues^{1,2}




Revenue (DKKm)
 — Reported growth (%)
- - - Organic growth (%)

Coloplast revenue development by geography and total


Europe




Other Developed Markets



Emerging Markets




Coloplast group



Revenue (DKKm)
 — Reported growth (%)
 - - - - - Organic growth (%)


Gross margin & cost items development

Gross Profit development, %



Note: FY 22/23 Gross Profit negatively impacted by inflationary headwind on input costs (raw materials, energy, wage increases in Hungary). FY 23/24 Gross Profit includes positive impact of around 100bps from Kerecis and favourable development in input costs, partly offset by wage inflation in Hungary, ramp-up costs in Costa Rica and negative currency impact.


Cost item, % of revenue*



Note: PPA amortisation related to the Atos Medical and Kerecis acquisitions included under distribution costs (Atos Medical included as of FY 21/22 and full-year impact as of FY 22/23; Kerecis included as of FY 22/23 and full-year impact as of FY 23/24)

Segment operating profit (Excludes shared/non-allocated costs)

Segment Operating Profit DKKm
 Segment Operating Profit Margin (%)



1. Segment operating profit for Voice & Respiratory Care and Biologics is excluding PPA amortisation expenditures.


2. FY 21/22 for Voice & Respiratory Care includes eight months of impact.

3. Biologics is Coloplast's new business area, added with the acquisition of Kerecis.

R&D costs for Interventional Urology, Voice and Respiratory Care, and Biologics are included in the segment operating profit/loss for the respective segments, while R&D costs for Chronic Care and Advanced Wound Care are shared between functions and included under shared/non-allocated costs. Financial items and income tax are not allocated to operating segments.

EBIT margin of 26%¹ in H1: ~70 basis points negative impact from currencies and ~40 basis points negative impact from Kerecis


H1 2025/26 EBIT margin development before special items (%)



H1 2025/26 highlights


- **Gross margin** of 67%, compared to 68% last year.
 - Negative impact from currencies (~60 basis points) and ramp-up costs in Costa Rica and Portugal.
 - Positive impact from lower inflation on freight versus last year.
- **Operating expenses** amounted to DKK 5,782 million, a 2% increase from last year.
 - Distribution-to-sales ratio was 33%, on par with last year. Distribution costs grew 0%. The flat development reflects one-off logistics costs in the US last year, and lower sales costs in China this year, partly offset by Kerecis one-off costs this year.
 - The Admin-to-sales ratio was 5% vs. 4% last year and includes around DKK 15 million in one-off advisory costs incurred by Kerecis in connection with the recent CMS regulatory changes in the US out-patient setting.
 - The R&D-to-sales ratio was 4% vs. 3% last year, driven by higher activity levels in Chronic Care and Kerecis.
- **EBIT before special items** amounted to DKK 3,670 million, a 3% decrease from last year. The reported EBIT margin before special items was 26%, against 27% last year, reflecting ~70 basis points negative impact from currencies and ~40 basis points negative impact from Kerecis.

H1 2025/26 EBIT margin: Impact from Atos Medical and Kerecis PPA amortisation




Key drivers of free cash flow to sales: taxation, working capital, and CAPEX optimisation

Taxation




- H1 25/26 effective tax rate of 22%, on par with the ordinary tax rate last year.
 - The total tax expense last year included an extraordinary expense of DKK 587 million related to the transfer of Kerecis' Intellectual Property (IP) from Iceland to Denmark, consistent with Coloplast's principal tax model.
- FY 25/26 tax rate expected around 22%
- Coloplast's tax rate during the Impact4 strategic period is expected to be around 22%, benefiting from the recent IP transfers (Atos Medical and Kerecis)

Net working capital



- H1 25/26 NWC-to-sales of 25%, against 26% on 30 September 2025.
- FY 25/26 NWC-to-sales expected around 25%
- Working capital-to-sales ratio expected to improve to around 24% in the Impact4 strategic period, impacted by:
 - Growth in mature markets
 - Growth in Emerging markets, which have long credit times
 - Increasing inventory levels on strategic raw materials and products


CAPEX¹




- H1 25/26 CAPEX-to-sales ratio of 6%, compared to 4% last year, includes investments in new manufacturing site in Portugal and innovation capex.
- FY 25/26 CAPEX-to-sales ratio expected to be around 5%. Includes continued investments in the new manufacturing site in Portugal of 30,000 m², expected to be operational in Q4 2025/26.
- Capex-to-sales ratio in the Impact4 strategic period is expected to be 4-5%, with a reduction to around 4% towards the end of the period.
- H1 25/26 depreciation and amortisation includes PPA amortisation of DKK 158 million (Atos Medical and Kerecis)

Exchange rate exposure FY 2025/26 and hedging policy

Revenue FX exposure 2025/26¹⁾



12 months exposure from 10% initial exchange rate drop¹⁾



Foreign exchange rate guidance for 2025/26

| Currency | Average exchange rate FY 2024/25 ¹⁾ | Spot rate, May 8, 2026 | Estimated average exchange rate 2025/26 ³⁾ | Change in estimated average exchange rate compared to last year | Average exchange rate H1 2024/25 | Average exchange rate H1 2025/26 | Change in average exchange rates for H1 compared to H1 last year |
|-----------------------------------|--|------------------------|---|---|----------------------------------|----------------------------------|--|
| Key currencies: | | | | | | | |
| USD | 676 | 636 | 638 | -6% | 704 | 640 | -9% |
| GBP | 882 | 864 | 860 | -3% | 895 | 857 | -4% |
| HUF | 1.85 | 2.10 | 2.02 | 9% | 1.84 | 1.94 | 5% |
| Other selected currencies: | | | | | | | |
| CNY | 94 | 94 | 92 | -2% | 97 | 91 | -6% |
| JPY | 4.53 | 4.06 | 4.09 | -10% | 4.62 | 4.12 | -11% |
| AUD | 435 | 460 | 446 | 2% | 451 | 432 | -4% |
| BRL | 119 | 129 | 125 | 5% | 121 | 120 | 0% |
| ARS ²⁾ | 0.47 | 0.46 | 0.46 | -2% | 0.65 | 0.47 | -28% |

Hedging Policy

To achieve the objective of a stable income statement we hedge:

- Key currencies e.g., USD, GBP, HUF using forward contracts and options. Not EUR
- On average 10-12 months
- Selected balance sheet items in foreign currency and part of the expected rolling 12-month cash flows
- Taking risk. vs. cost of hedging into consideration

1) Average exchange rate from October 1, 2024 to September 30, 2025.

2) The hyperinflationary economy in Argentina entails that results denominated in Argentinian Peso must be adjusted for inflation and be translated at the exchange rate of the balance sheet day which was DKK 0.65 per ARS 100.00 at March 31, 2025, DKK 0.47 per ARS 100.00 at September 30, 2025 and DKK 0.47 per ARS 100.00 at March 31, 2026.

3) Estimated average exchange rate is calculated as the average exchange rate year for the first six months combined with the spot rates at May 8, 2026

Capital structure

Highlights

Overall policy is that **excess liquidity is returned to shareholders** through a combination of dividends (paid bi-annually) and share buy-backs. Coloplast will not initiate a share buy-back program in FY 2025/26 as treasury shares are sufficient to hedge outstanding employee share options.

Interest bearing debt will only be raised in connection with a major acquisition or other special purposes.

FY 21/22 increase in net interest bearing debt (NIBD) driven primarily by the Eurobond issuance of EUR 2.2bn in 2022 related to the Atos Medical acquisition.

FY 23/24: Increase in NIBD driven by debt raised to cover the extraordinary tax payment made in Q2, related to the transfer of Atos Medical's Intellectual Property.


FY 23/24: 2-year bond of EUR 650m, which expired 19 May 2024, was refinanced through a committed term loan (terms: CIBOR 3M+80bps).

FY 25/26: Refinancing of EUR 800m revolving credit facility (RCF) in January 2026. The facility retains the same terms and conditions and matures in January 2029. The structure remains a standard RCF.

Coloplast has a **credit rating of BBB+** by S&P Global Ratings (latest rating as of June 2024).

Coloplast is committed to deleveraging and bringing the gearing ratio down to **around 1.5x EBITDA** towards 2029/30

Net interest-bearing debt




1) Before special items

Coloplast manufacturing footprint and COGS categories


Production by country (Volume)¹

- Hungary
- US/France
- Costa Rica
- China
- Atos (SE/DE)
- Kerecis (Iceland)



COGS by cost type²

- Salary - Direct
- Salary - Indirect
- Materials (RM &SFG)
- Depreciations & amortisations
- Energy
- Freight
- Other




Volume and specialised production sites⁴



- High Volume Production
- High Volume Production under construction
- Innovation & Pilot Centre
- Specialised Production

Q1 2025/26 progress on key sustainability ambitions





Appendices

Leading intimate healthcare




The Coloplast share (COLO-B.CO)

Coloplast share listed on [Nasdaq Copenhagen](#) since 1983

~90.3 billion DKK (~14 billion USD) market cap @ ~400.50 DKK per share (incl. A shares)

Two share classes:

- 18m **A shares carry** 10 votes (family)
- 210.2m **B shares carry** 1 vote (freely traded)
- **Free float approx.** 54% (B shares)



Note: Share capital ownership as per September 2025

¹ Holders of A shares and family hold 68% of the votes in Coloplast

Immaterial impact from tariffs expected as most products are currently exempt, but depends on outcome from section 232

Chronic Care

No exposure – products for the management of chronic care conditions are currently exempt.

Voice & Respiratory Care

No exposure – products for the management of chronic care conditions are currently exempt.


Advanced Wound Care

Limited exposure with some products exempt.

Interventional Urology

Limited exposure as key products for the US market, primarily from the Men's Health segment, are manufactured in the US.

Timeline of CMS Skin substitutes reforms



We continuously monitor the healthcare reimbursement environment. We expect neutral impact from pricing over the Impact4 strategic period

Europe:

Netherlands

Reimbursement pressure on both OC and CC.

France

Reimbursement pressure on AWD, OC (Supporting products) and IC.

Italy

Retroactive regional payback system

Germany

Potential price reform on AWD.

Rest of World:

US Biologics

Fixed payment of USD 127/cm² implemented January 1, 2026 in the Medicare outpatient setting.

US Chronic

OC and CC products included in the Nationwide Remote Item Delivery Competitive Bidding Programme (Medicare coverage).

According to CMS, contracts under the CBP expected to take effect no later than January 1, 2028.

US IC

CMS established three new dedicated codes for hydrophilic catheters, with implementation date as of January 1, 2026.

Sustainability - key priorities and actions

Use less materials



Net Zero by 2045



Positively impact people



Why is this a key priority:

As a manufacturer of medical products made primarily of plastic, Coloplast embraces the responsibility to contribute to solving the problems with plastic waste, whilst maintaining the highest level of product safety. We will use fewer resources, targeting a 15– 20%¹ reduction in product and packaging materials by 2030.

How will we achieve this?

- Redesign packaging for optimal material use
- Use more sustainable materials in products
- Increase the share of recycled materials used in primary, secondary and tertiary packaging
- Explore options for material re-use and recycling in our own operations

Why is this a key priority:

Sustainability remains a core strategic priority, supported by clear and measurable targets, where we aim for Net Zero by 2045. In Impact4, we will reduce our environmental footprint by lowering scope 1+2 emissions by 90%¹ and scope 3 emissions per product by 10%¹ by 2029/30.

How will we achieve this?

- Scope 1 & 2:
 - Renewable energy usage by switching to Power Purchase Agreements (PPAs) and phasing out natural gas
 - Converting company cars to electric vehicles
- Scope 3:
 - Use lower carbon footprint materials in legacy portfolio (products and packaging)
 - Enable our suppliers to set targets and reduce emissions
 - Limit goods transported by air and business travel

Why is this a key priority:

Coloplast is a people's business. We want to ensure access to our products for people in need. Our people and culture are at the center of our Impact4 strategy. Maintaining and developing a safe, inclusive and diverse working environment is key to delivering on our strategy.

How will we achieve this?

- Users & HCPs
 - Reimbursement improvements in ~5 markets
- Employees
 - Reducing loss-time injury frequency through job-specific training – reach LTIs of 1.5 PPM or less
 - Increasing the % of female representation at Vice President+ level through natural turnover and senior leadership focus
 - Engaged workforce and reach Employee Engagement score in the top quartile of our industry
 - Code of conduct: 100% completion

M&A played a bigger role during Strive25

← Opportunity based →

Systematic screening



2022

- The leader in the attractive chronic laryngectomy market
- Around 75% of the purchase value (around DKK 16 billion) treated as goodwill
- Remaining 25% treated as intangibles, to be amortised over approximately 15 years (around DKK 200 million PPA amortisation per year)
- Structured as a 100% cash payment financed through debt financing
- Acquisition completed on 31 January 2022
- Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure by FY 2024/25
- Increasingly EPS accretive from FY 2022/23



2023

- Fastest growing company in the biologics wound care segment
- Acquired at an enterprise value of up to USD 1.3 billion (DKK ~8.9 billion).
- Total price for 100% of the share capital is USD 1.2 billion (DKK ~8.2 billion), on a cash and debt free basis
- Transaction financed through an equity issue, completed 30 August 2023
- Acquisition completed on 31 August 2023
- Business case: Three-year revenue CAGR of ~30% until FY 2025/26 and EBIT margin of ~20% in FY 2025/26
- Attractive gross margin level, accretive to Coloplast
- Transaction increasingly EPS accretive from FY 2026/27

Early-stage technologies

Nine Continents Medical (Intibia)

2020

Portfolio expansion

TFL Drive
(distribution agreement)

Channel expansion

US direct-to-consumer
DME dealers¹

Introducing Ostomy Care

- Between 3 and 4 million people live with a stoma globally, ~2/3 in the developed markets
- Up to around 500,000 stoma surgeries per year in developed markets and China

Disease areas

- Colorectal cancer (est. 45%)
- Bladder cancer (est. 10%)
- Diverticulitis (est. 15%)
- Inflammatory bowel disease (est. 10%)
- Other (est. 20%)

Customer groups

- Nurses, mainly stoma care nurses
- People with a stoma
- Wholesalers/distribution
- Hospital purchasers and GPOs
- Surgeons

Call points

- Hospital & community nurses
- Hospital buyers
- Distributors
- Dealers
- Wholesalers
- Homecare companies

Key products



SenSura® Mio in black
Launch initiated in 2024



SenSura® Mio Concave
Launched in 2018-2019



SenSura® Mio Convex
Launched in 2015



SenSura® Mio
Launched in 2014



SenSura®
Launched in 2006-2008




Assura® new generation
Launched in 1998



Alterna® original
Launched in 1991

Distribution of revenues*

- Urostomy
- Ileostomy
- Colostomy



* Excluding baseplates, hospital assortment, sets and supporting products

Introducing Ostomy Care Supporting Products

Market fundamentals

- Market size of DKK 4-5bn
- Market growth of 6-8%
- Market share 35-40%
- Main competitors include Hollister Adapt, ConvaTec, 3M Cavilon, Eakin

Customer groups & call points

- Nurses, mainly stoma care nurses
- People with a stoma
- Wholesalers/distributors
- Hospital purchasers and GPOs
- Surgeons

Brava® is a range of ostomy supporting products designed to reduce leakage or care for skin, to make our end-users feel secure. The Brava portfolio was launched in 2012.

Key products



Heylo
Digital leakage notification system
(launched in the UK in 2024)



Brava® Protective Seal
Designed for leakage and skin protection



Brava® Skin Barrier
Reducing skin problems without affecting adhesion



Brava® Elastic Tape
Elastic so it follows the body and movements



Brava® Protective Seal Convex
Designed for leakage and skin protection




Brava® Adhesive Remover
Sting free and skin friendly



Brava® Lubricating Deodorant
Neutralizing odour

Distribution of revenues

- European markets
- Other developed markets
- Emerging markets



Introducing Continence Care

- Intermittent catheters for management of urinary retention and collecting devices for management of urinary incontinence
- Around 12 to 18 million people live with urinary retention globally. Only about half of them are discharged on an intermittent catheter and half of them drops out in the first five years due to physical and mental barriers

Disease areas

- Spinal Cord Injured, SCI
- Spina Bifida, SB
- Multiple Sclerosis, MS
- Benign prostatic hyperplasia (BPH) & prostatectomy patients
- Elderly

Customer groups

- Continence or home care nurses
- Wholesalers/distributors
- Hospital purchasers and GPOs

Main call points

- Rehabilitation centres
- Urology wards
- Distributors, dealers & wholesalers

Key products



Luja™ Intermittent catheter with Micro-hole Zone Technology™
Launched in 2023 (male) and 2024 (female)



SpeediCath® Flex Set Intermittent Set catheter
Launch during 2022-2023



SpeediCath® Navi Intermittent catheter
Launched in 2019-2020



SpeediCath® Flex Intermittent catheter
Launched in 2016



SpeediCath® Compact Eve Intermittent catheter
Launched in 2014



SpeediCath® Compact Male Intermittent catheter
Launched in 2011



SpeediCath® Standard Intermittent catheter
Launched in 1999




Conveen® Optima External catheter
Launched in 2005-2006



Conveen® Security+
Launched in 2013

Distribution of revenues

- Intermittent catheters
- Collecting devices (Urine bags & Urisheaths)
- Bowel management
- CC Other



Introducing Bowel Care

Market fundamentals

- Market size for transanal irrigation more than DKK 1bn
- Around double-digit market growth

Disease areas

Chronic constipation
Faecal incontinence

Customer groups

- Spinal Cord Injured
- Spina Bifida
- Multiple Sclerosis

Call points

- Rehab centers
- Pediatric clinics
- Urology wards

Key products



Peristeen® Light
Transanal Irrigation
175ml Launched in 2024
250ml Launched in 2025



Peristeen® Plus
Transanal Irrigation
Launched in 2021




Peristeen®
Transanal Irrigation
Launched in 2003; Updated in 2011

Market dynamics

- | | |
|---|---|
| + Growing awareness | ÷ Still taboo area and non-focus for healthcare professionals |
| + Significant under-penetration and unserved population | ÷ Limited patient awareness |
| + New devices addressing the many unmet needs | ÷ Training required (nurses, patients) |
| | ÷ Lack of reimbursement |

Distribution of revenues

- Europe
- Other developed
- Emerging markets



Introducing Voice & Respiratory Care Laryngectomy

Disease areas

- People that have undergone a total laryngectomy, a typical treatment for advanced laryngeal and hypopharyngeal cancer and cancer recurrence

Market dynamics

- 50,000 new total laryngectomy (TL) surgeries performed annually
- Only ~1/3 of patients undergoing TL surgery are treated with products, of which only ~50% use the appropriate amount of products
- Average value per patient is DKK 20-30,000 in mature market

Key products - Laryngectomy

Provox® Life™ Heat and Moisture Exchangers (HMEs)



Home Go Night Protect Energy Free hands

Provox® Life™ Adhesive



Standard Sensitive Stability Night

Provox® HMEs



Micron



XtraFlow

Accessories



Provox® Adhesive remover



Provox® Skin barrier

Voice Prostheses



Provox® Vega




Provox® Vega XtraSeal



Provox® ActiValve

Distribution of revenues

- HMEs
- Adhesives
- Voice Prostheses
- Accessories



Introducing Voice & Respiratory Care Tracheostomy

Disease areas

- Performed when the airways are restricted, e.g., during an emergency when the airways are blocked, or when a disease or other problem makes normal breathing impossible
- Can be temporary or permanent

Market dynamics

- 1-1.5 million estimated number of procedures globally
- Estimated 20% are permanent (across different patient groups, for example neck and throat cancer patients, neurological diseases, patients with chronic obstructive pulmonary diseases), the rest 80% are temporary
- The market today mainly consists of tubes used for breathing

Key products - Tracheostomy



Freevent® XtraCare™



TrachPhone®



Freevent® DualCare™



Tracoe® twist
Tracheostomy Tube



Portfolio expansion

- Strengthened the tracheostomy product portfolio with the acquisition of the Tracoe® Group
- The Tracoe Group develops, manufactures and sells a full and complementary range of tracheostomy care products, including percutaneous dilation sets for the beginning of care

Introducing Interventional Urology

- **Men's Health:** men with erectile dysfunction. ~25% of men aged 40-70 years old experience moderate to severe erectile dysfunction.
- **Women's Health:** women with pelvic organ prolapse and stress urinary incontinence. ~50% of women 50-79 years old report experiencing pelvic organ prolapse symptoms. An estimated 32% of women suffer from stress or mixed urinary incontinence.

Disease areas

- Urinary incontinence
- Pelvic organ prolapse
- Erectile dysfunction
- Enlarged prostate
- Kidney and urinary stones

Customer groups

- Surgeons
- Purchasing departments and organizations
- End customers

Call points

- Urologists
- Uro-gynaecologists
- Gynaecologists
- Purchasing departments and organizations

Key products



Thulium Fiber Laser Drive
Launched in 2022
Endourology



Titan® Touch Inflation Penile Prosthesis
Launched in 2013, Men's health




Altis® single incision sling
Launched in 2012
Women's health – Surgical Urology



JJ stents
Launched in 1998
Single use devices

Distribution of revenues

- Men's Health
- Women's Health
- Single use devices



Introducing Wound & Tissue Repair

Disease areas

Chronic wounds

- Leg ulcers
- Diabetic foot ulcers
- Pressure ulcers

Other wound types:

- Surgical
- Burn

Customer groups & call points


Hospitals

- Wound care committees
- Specialist nurses/doctors
- (Purchasers)

Community

- Specialist nurses/doctors
- General practitioners
- District/general nurses
- Large nursing homes

Key products



Biatain® Superabsorber
Non-adhesive dressing for high volumes of exudate
Launched in 2024




Biatain® Silicone Fit
Silicone foam dressing for pressure injury prevention and wound management.
Launched in 2024 in the US




Biatain® Silicone Non-Border
Silicone foam dressing without a border.
Launched in 2021



Biatain® Fiber
Reinforced gelling fiber.
Launched in 2020
Ag-version launched in 2025



Biatain® Silicone
Foam dressing with gentle silicone adhesive.
Launched in 2016
Ag-version launched in 2018



Comfeel® Plus
Hydrocolloid dressing.
Relaunched in 2016




Shield®
Features a borderless silicone contact layer protecting the intact fish skin.
Launched in 2023



SurgiClose®
Intact fish skin graft.
Launched in 2021

Distribution of revenues*

- Biologics
- Foams and Fibers
- Comfeel
- WC other



* Excluding Contract manufacturing

Income statement

| DKK m | Q2 2025/26 | Q2 2024/25 | Change | H1 2025/26 | H1 2024/25 | Change |
|---|---------------|--------------|--------------|---------------|---------------|-------------|
| Revenue | 7,084 | 6,930 | 2% | 14,127 | 13,956 | 1% |
| Gross profit | 4,717 | 4,728 | 0% | 9,452 | 9,478 | 0% |
| SG&A costs | -2,666 | -2,626 | 2% | -5,310 | -5,250 | 1% |
| R&D costs | -254 | -239 | 6% | -501 | -458 | 9% |
| Other operating income/expenses | 23 | 28 | nm | 29 | 33 | -12% |
| Operating profit (EBIT) before special items | 1,820 | 1,891 | -4% | 3,670 | 3,803 | -3% |
| Special items | -3,025 | -84 | nm | -3,060 | -158 | nm |
| Operating profit (EBIT) | -1,205 | 1,807 | -167% | 610 | 3,645 | -83% |
| Net financial items | -39 | -316 | -88% | -63 | -385 | -84% |
| Tax | 273 | -394 | -169% | -121 | -1,304 | -91% |
| Net profit | -971 | 1,097 | -189% | 426 | 1,956 | -78% |
| Adjusted¹⁾ net profit before special items | 1,389 | 1,299 | 7% | 2,813 | 2,666 | 6% |
| Key ratios | | | | | | |
| Gross margin | 67% | 68% | | 67% | 68% | |
| EBIT margin before special items | 26% | 27% | | 26% | 27% | |
| EBIT margin | -17% | 26% | | 4% | 26% | |
| Earnings per share (EPS) before special items, diluted | 6.16 | 4.34 | 42% | 12.48 | 9.23 | 35% |
| Adjusted ¹⁾ earnings per share (EPS) before special items, diluted | 6.16 | 5.45 | 13% | 12.48 | 11.08 | 13% |

Balance sheet

| DKKm | 31 Mar 2026 | 31 Mar 2025 | Change |
|--|---------------|---------------|-------------|
| Balance, total | 46,649 | 49,152 | -5% |
| Assets | | | |
| Non-current assets | 36,196 | 38,685 | -6% |
| Current assets | 10,453 | 10,467 | 0% |
| <i>of which:</i> | | | |
| Inventories | 3,942 | 3,797 | 4% |
| Trade receivables | 4,587 | 4,752 | -3% |
| Marketable securities, cash, and cash equivalents | 1,067 | 729 | 46% |
| Other receivables | 307 | 353 | -13% |
| Equity and liabilities | | | |
| Total equity | 12,843 | 16,942 | -24% |
| Non-current liabilities | 27,827 | 21,243 | 31% |
| Current liabilities | 5,979 | 10,967 | -45% |
| <i>of which:</i> | | | |
| Trade payables | 1,368 | 1,211 | 13% |
| Other credit institutions | 1,974 | 6,673 | -70% |
| Income tax | 64 | 596 | -89% |
| Other payables | 2,240 | 2,172 | 3% |
| Key ratios | | | |
| Equity ratio | 28% | 34% | |
| Invested capital | 36,959 | 41,432 | -11% |
| Return on average invested capital before tax (ROIC) ¹⁾ | 19% | 18% | |
| Return on average invested capital after tax (ROIC) ¹⁾ | 15% | 11% | |
| Adjusted ²⁾ return on average invested capital after tax (ROIC) ¹⁾ | 15% | 15% | |
| Net asset value per share, DKK | 57 | 75 | -24% |

1)Before special items. After special items, ROIC before tax was 18% (2023/24: 19%), and ROIC after tax was 11% (2023/24: 15%).

2)Adjusted for the impact from the Kerecis IP transfer YTD 2025/24

Cash flow

| DKKm | H1 2025/26 | H1 2024/25 | Change |
|---|---------------|--------------|--------------|
| EBIT | 610 | 3,645 | -83% |
| Amortisation | 3,250 | 244 | 1232% |
| Depreciation | 444 | 428 | 4% |
| Adjustment for other non-cash operating items | 75 | 34 | 121% |
| Change in working capital | -323 | -915 | -65% |
| Net Financial items | -45 | -438 | -90% |
| Paid tax | -312 | -249 | 25% |
| Cash flow from operations | 3,699 | 2,749 | 35% |
| CAPEX ¹ | -863 | -618 | 40% |
| Property, plant and equipment sold | 9 | 5 | 80% |
| Investment in other investments | -29 | -21 | 38% |
| Company divestments | - | 192 | nm |
| Acquisitions of subsidiaries | -141 | - | nm |
| Cash flow from investments | -1,024 | -442 | 132% |
| Free cash flow | 2,675 | 2,307 | 16% |
| Dividends | -4,057 | -3,831 | 6% |
| Net aquisition of treasury shares and exercise of share options | - | 27 | -100% |
| Repayment of lease liabilities | -142 | -143 | -1% |
| Financing through debt funding | 1,977 | - | - |
| Movements on credit facilities | -354 | 1,588 | -122% |
| Net cash flow | 99 | -52 | -290% |

Production sites

Hungary

Tatabánya



- Ostomy care products
- Adhesives
- Contenance care products
- Interventional Urology products
- Number of employees in production: ~1,700

Tatabánya PDC



- Postponement & packaging
- Cross docking
- Warehousing
- Distribution & shipping
- Number of employees: ~450

Nyírbátor



- Contenance care products
- Wound care products
- Consumer products
- Number of employees in production: ~2,900

China

Zhuhai



- Contenance care products
- Ostomy care products
- Machine building
- Number of employees in production: ~700

Costa Rica

Cartago



- The first high volume production site became operational in Q2 2020/21
- The second high volume production site opened in Q3 2021/22
- Ostomy care and continence care products
- Number of employees in production: ~1,200

Denmark

Mørdrup



- Pilot development work Ostomy care, Contenance care and Wound care
- Adhesives production
- Number of employees in production: ~230

Production sites

Portugal

Felgueiras



- High volume production under construction
- The new manufacturing site of 30,000 m², expected to be operational in FY 2025/26
- Number of employees in production: ~160

France

Sarlat



- Disposable surgical urology products
- Number of employees in production: ~240

US

Minneapolis



- Interventional Urology products
- Number of employees in production: ~100

Sweden

Hörby



- Research & Development centre and manufacturing of laryngectomy products
- Number of employees in production: ~180

Germany

Nieder-Olm



- Specialised production
- Research & Development centre and manufacturing of tracheostomy products
- Number of employees in production: ~240

Iceland

Isafjordur



- Specialised production
- Research & Development centre and manufacturing of biologics wound care products
- Number of employees in production: ~80

Coloplast Sponsored Level 1 ADR programme

| Coloplast Sponsored ADR Programme | |
|-----------------------------------|----------------------------|
| Symbol | CLPBY |
| Structure | Level 1 ADR |
| Exchange | OTC |
| CUSIP | 19624Y101 |
| DR ISIN | US19624Y1010 |
| Ratio | 10 ADRs : 1 ordinary share |
| Country | Denmark |
| Underlying SEDOL | B8FMRX8 |
| Underlying ISIN | DK0060448595 |
| Depository Bank | BNY Mellon |

Benefits of a Coloplast ADR programme to US Investors:

- Coloplast has established a sponsored ADR programme in the US, as a service to US investors by offering an alternative way to trade Coloplast shares, while serving to further broaden the company's shareholder base over the long term.
- Clear and settle according to normal US standards
- Offer the convenience of stock quotes and dividend payments in US dollars
- Can be purchased/sold in the same way as other US stocks via a US broker
- Provide a cost-effective means of international portfolio diversification
- Ability to acquire the underlying securities directly upon cancellation

For questions about creating Coloplast ADRs, please contact BNY Mellon:

New York
Rick Maehr:
Direct tel.: +1 212 815 2275
adrdesk@bnymellon.com

London
Mark Lewis:
Direct tel.: +44 207 163 7407
adrdesk@bnymellon.com

Contact Investor Relations



Kristine Husted Munk
Senior Director, Investor Relations
Tel. direct: +45 4911 3266
Office: +45 4911 1800
dkkhu@coloplast.com



Simone Dyrby Helvind
Senior Manager, Investor Relations
Tel. direct: +45 4911 2981
Office: +45 4911 1800
dksdk@coloplast.com



Aleksandra Dimovska
Vice President, Investor Relations
On maternity leave

Holtevej 1
DK-3050 Humlebæk
Denmark



Julie Müggler
Coordinator & PA, Investor Relations
Tel. direct: +45 4911 3161
Office: +45 4911 1800
dkjasm@coloplast.com



Konstancija Norvilaite
Associate IR & Finance Manager
Tel. direct: +45 4911 2803
Office: +45 4911 1800
dkkono@coloplast.com

The Coloplast story begins back in 1954. Elise Sørensen is a nurse. Her sister Thora has just had an ostomy operation and is afraid to go out in public, fearing that her stoma might leak. Listening to her sister's problems, Elise conceives the idea of the world's first adhesive ostomy bag.

Based on Elise's idea, Aage Louis-Hansen, a civil engineer and plastics manufacturer, and his wife Johanne Louis-Hansen, a trained nurse, created the ostomy bag. A bag that does not leak, giving Thora – and thousands of people like her – the chance to live the life they want.

A simple solution that makes a difference.

Today, the Coloplast Group develops products and services that help millions of people live more independent lives through solutions tailored to their needs. Globally, our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology.

Mission

Making life easier for people with intimate healthcare needs

Values

Closeness... to better understand

Passion... to make a difference

Respect and responsibility... to guide us

Vision

Setting the global standard for listening and responding